Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Longbio Pharma (Suzhou) Co FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Longbio Pharma (Suzhou) Co FCF Yield % Related Terms
Longbio Pharma (Suzhou) Co FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longbio Pharma (Suzhou) Co FCF Yield % Chart
Longbio Pharma (Suzhou) Co Annual Data
Trend
Dec24
Dec25
FCF Yield %
0.00
0.00
Longbio Pharma (Suzhou) Co Semi-Annual Data
Dec24
Dec25
FCF Yield %
0.00
0.00
HKSE:01779 vs VRTX, REGN, RVMD: FCF Yield % Comparison
For the Biotechnology subindustry, Longbio Pharma (Suzhou) Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Longbio Pharma (Suzhou) Co FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Longbio Pharma (Suzhou) Co's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Longbio Pharma (Suzhou) Co's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longbio Pharma (Suzhou) Co (HKSE:01779) has a FCF Yield % of -1.53 as of Aug. 10, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Longbio Pharma (Suzhou) Co and its competitors. According to the industry distribution chart, Longbio Pharma (Suzhou) Co ranks #320 out of 1408 companies in the Biotechnology industry, placing it in the top 22.7%.
Is Longbio Pharma (Suzhou) Co's FCF Yield % too high?
Longbio Pharma (Suzhou) Co's current FCF Yield % is -1.53. Based on the distribution chart, Longbio Pharma (Suzhou) Co ranks #320 out of 1408 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Longbio Pharma (Suzhou) Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Longbio Pharma (Suzhou) Co's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Longbio Pharma (Suzhou) Co ranks #320 out of 1408 companies for FCF Yield %. This places Longbio Pharma (Suzhou) Co in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Longbio Pharma (Suzhou) Co and its competitors. Longbio Pharma (Suzhou) Co's current FCF Yield % is -1.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longbio Pharma (Suzhou) Co stock overvalued right now?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a current FCF Yield % of -1.53. The current FCF Yield % is -1.53. Longbio Pharma (Suzhou) Co's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Longbio Pharma (Suzhou) Co (HKSE:01779), the current FCF Yield % is -1.53 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
10GF Score
Get the complete analysis for HKSE:01779
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01779 has been successfully added to your 
